Article
Oncology
Gabriela Silva, Joana Sales-Dias, Diogo Casal, Sara Alves, Giacomo Domenici, Clara Barreto, Carolina Matos, Ana R. Lemos, Ana T. Matias, Khrystyna Kucheryava, Andreia Ferreira, Maria Raquel Moita, Sofia Braga, Catarina Brito, M. Guadalupe Cabral, Cristina Casalou, Duarte C. Barral, Pedro M. F. Sousa, Paula A. Videira, Tiago M. Bandeiras, Ana Barbas
Summary: The study found that the anti-DLL1 antibody can inhibit BC cell proliferation, mammosphere formation, angiogenesis, as well as have anti-tumor and anti-metastatic efficacy in an ER+ BC mouse model without side effects, indicating its potential as a promising candidate for ER+ BC treatment.
Article
Oncology
Tomohiro Tanaka, Tomokazu Ohishi, Teizo Asano, Junko Takei, Ren Nanamiya, Hideki Hosono, Masato Sano, Hiroyuki Harada, Manabu Kawada, Mika K. Kaneko, Yukinari Kato
Summary: The monoclonal antibody TrMab-6 demonstrated strong in vitro antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities against CHO/TROP2 and three breast cancer cell lines, and significantly reduced tumor growth in mouse xenograft models, suggesting its promising potential as a treatment option for TROP2-expressing breast cancers.
Article
Biochemistry & Molecular Biology
Li Yang, Xuhui Wang, Jiawei Sun, Chunyan Liu, Guoxiang Li, Jingling Zhu, Jin Huang
Summary: Neuritin plays a crucial role in angiogenesis and may affect angiogenesis by inhibiting the Notch signaling pathway. The expression of Neuritin is decreased in lung cancer vascular tissue but is correlated with increased vascular density. Overexpression of Neuritin can suppress the Notch signaling pathway and enhance the migration and tubular formation of HUVECs.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
(2021)
Article
Nanoscience & Nanotechnology
Wei Chen, Xiaohong Yang
Summary: This study aimed to investigate the effect of dual antiplatelet therapy (DAPT) on cardiac dysfunction in psoriasis. The results showed that DAPT alleviated cardiac dysfunction caused by psoriasis by inhibiting angiogenesis and regulating the Notch/DLL4 pathway.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
(2022)
Article
Oncology
Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C. J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen Clouse, Vicky Borders-Hemphill, Lindsey Brown, Candace Gomez-Broughton, Zhong Li, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi-Ming Tu, Bellinda King-Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: Margetuximab-cmkb in combination with chemotherapy was granted regular FDA approval for the treatment of HER2-positive metastatic breast cancer patients who have received two or more prior anti-HER2 regimens. The SOPHIA study demonstrated that margetuximab had a longer median progression-free survival compared to trastuzumab when both were combined with chemotherapy. Infusion-related reactions were reported as important safety signals associated with margetuximab plus chemotherapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, Research & Experimental
Nayanendu Saha, Du-San Baek, Rachelle P. Mendoza, Dorothea Robev, Yan Xu, Yehuda Goldgur, M. Jason De La Cruz, Elisa de Stanchina, Peter W. Janes, Kai Xu, Dimiter S. Dimitrov, Dimitar B. Nikolov
Summary: Metastasis and chemoresistance in colorectal cancer can be inhibited by targeting the substrate-binding region of ADAM10, a metalloprotease that regulates Notch signaling in certain cancer stem cells. A human monoclonal antibody named 1H5 was developed to bind to the substrate-binding domain of ADAM10, inhibiting Notch cleavage and proliferation of colon cancer cells. In mouse models, 1H5 combined with Irinotecan showed highly effective tumor growth inhibition without toxicity. This approach overcomes the limitations of small molecule inhibitors that target the protease active site and exhibit musculoskeletal toxicity.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Immunology
Alireza Shoari, Mehdi Tahmasebi, Farnaz Khodabakhsh, Reza Ahangari Cohan, Akbar Oghalaie, Mahdi Behdani
Summary: Monoclonal antibodies, though effective, have limitations in cancer therapy. Nanobodies, small antigen binding antibody fragments, show promise in cancer research, diagnosis, and treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Oncology
Kathrine Lundo, Oksana Dmytriyeva, Louise Spohr, Eliana Goncalves-Alves, Jiayi Yao, Laia P. Blasco, Mette Trauelsen, Muthulakshmi Ponniah, Marc Severin, Albin Sandelin, Marie Kveiborg, Thue W. Schwartz, Stine F. Pedersen
Summary: This study reveals the mechanism of lactate receptor GPR81 in breast cancer, which promotes tumor invasiveness by downregulating the Notch pathway ligand DLL4. This finding is of great significance for the treatment of breast cancer.
Article
Oncology
Tomohiro Tanaka, Hiroyuki Suzuki, Tomokazu Ohishi, Mika K. Kaneko, Yukinari Kato
Summary: H(2) Mab-77-mG(2a)-f possesses specific binding affinity to HER2-positive breast cancer cells and exhibits antitumor effects.
Article
Oncology
Charles L. Vogel, Melody A. Cobleigh, Debu Tripathy, John C. Gutheil, Lyndsay N. Harris, Louis Fehrenbacher, Dennis J. Slamon, Maureen Murphy, William F. Novotny, Michael Burchmore, Steven Shak, Stanford J. Stewart, Michael Press
Summary: The purpose of this study was to evaluate the efficacy and safety of single-agent trastuzumab as first-line treatment in women with HER2-positive metastatic breast cancer. The results showed that single-agent trastuzumab had good efficacy and tolerability in the treatment of HER2-positive metastatic breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Dong-Hoon Yeom, Yo-Seob Lee, Ilhwan Ryu, Sunju Lee, Byungje Sung, Han-Byul Lee, Dongin Kim, Jin-Hyung Ahn, Eunsin Ha, Yong-Soo Choi, Sang Hoon Lee, Weon-Kyoo You
Summary: DLL4 is a promising target to augment the effects of VEGF inhibitors, and a bispecific antibody ABL001 targeting both DLL4 and VEGF demonstrates more potent anti-cancer effects. The combination therapy of ABL001 with chemotherapy shows better efficacy in inhibiting tumor progression compared to monotherapy, possibly due to tumor vessel normalization.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Ting Yu, Yingxian Shi, Xinyan Pan, Qiang Feng, Peng Wang, Shuling Song, Lilin Yang, Julun Yang
Summary: In this study, the cell membrane penetrating peptide BR2 was used to deliver a broad-spectrum anti-p21Ras scFv gene into ganglioside expressing tumor cells. The fusion protein BR2-p21Ras scFv was found to specifically penetrate into tumor cells and bind with p21Ras, resulting in significant inhibition of tumor cell proliferation, migration, and colony formation, as well as promotion of apoptosis. This study suggests that BR2-p21Ras scFv has potential as a therapeutic antibody for ras-driven tumors.
Article
Multidisciplinary Sciences
Edward Seung, Zhen Xing, Lan Wu, Ercole Rao, Virna Cortez-Retamozo, Beatriz Ospina, Liqing Chen, Christian Beil, Zhili Song, Bailin Zhang, Mikhail Levit, Gejing Deng, Andrew Hebert, Patrick Kirby, Aiqun Li, Emma-Jane Poulton, Rita Vicente, Audrey Garrigou, Peter Piepenhagen, Greg Ulinski, Michele Sanicola-Nadel, Dinesh S. Bangari, Huawei Qiu, Lily Pao, Dmitri Wiederschain, Ronnie Wei, Zhi-yong Yang, Gary J. Nabel
Summary: A trispecific antibody targeting HER2 and T cells can inhibit breast cancer cell proliferation by stimulating CD4 T cells, and induce tumor regression in a humanized mouse model.
Review
Biotechnology & Applied Microbiology
Sandra M. Swain, Mythili Shastry, Erika Hamilton
Summary: The discovery of the monoclonal antibody trastuzumab almost 25 years ago revolutionized treatment and drug development for HER2(+) breast cancer. Here, Swain et al. review the current standard of care for HER2(+) breast cancer, describe mechanisms of drug resistance, and focus on next-generation platforms and therapies for the treatment of this disease.
NATURE REVIEWS DRUG DISCOVERY
(2023)
Article
Oncology
Maryam Khelil, Heather Griffin, Maaike C. G. Bleeker, Renske D. M. Steenbergen, Ke Zheng, Taylor Saunders-Wood, Sanne Samuels, Jossie Rotman, Wim Vos, Brendy E. van den Akker, Renee X. de Menezes, Gemma G. Kenter, John Doorbar, Ekaterina S. Jordanova
Summary: This study investigates origins of cervical cancer cells and describes a DLL-Notch1 phenotype associated with disease prognosis, potentially aiding in the identification of cells susceptible to HPV-induced carcinogenesis.
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.
